Goldman PE arm buys MyEyeDr in $2.7B deal, producing 3.5x return for Altas Partners

3 June 2019•2 mins read
optometry, ophthalmology, medical, private equity, vision care, M&A, healthcare, merger, Goldman Sachs, MyEyeDr, retail
LinkedInXEmail
LinkedInXEmail

Related articles